Agilent Technologies Inc. (NYSE: A) today announced that the Massachusetts Eye and Ear Infirmary, an affiliate of Harvard Medical School, has been authorized as a Certified Service Provider of Agilent’s next-generation target enrichment and microarray-based comparative genomic hybridization (aCGH) solutions. MEEI is home to the medical school’s Department of Ophthalmology Ocular Genomics Institute, which is working to harness the power of genomics and gene therapy to advance the knowledge and treatment of blinding eye diseases.
“Becoming an Agilent CSP enables us to provide the ocular genomics research community with access to the latest protocols and technologies we are using at Mass. Eye and Ear with ever-increasing success,” said Dr. Eric Pierce, director of the Ocular Genomics Institute. “It is our hope that these tools will help advance studies in genomic research and gene therapy. In addition, incorporating the Agilent Bravo Automated Liquid Handling platform into our service offerings will enable us to quickly process large volumes of samples for even more researchers and for a wide range of genomics applications. We are using these approaches to provide improved clinical genetic diagnostic testing services for patients with inherited eye disorders.”
“We are excited to have MEEI as part of the Agilent CSP program,” said Victor Fung, senior director of marketing for Agilent’s Genomics Solutions Division. “MEEI has used Agilent’s NGS target enrichment and aCGH solutions for several years in their retinal degeneration mutational disease research. We look forward to supporting them as they expand their services outside of the Harvard community.”
About the Agilent Certified Service Provider ProgramAgilent offers its CSP program to select service provider laboratories interested in using its market-leading technologies to provide the highest-quality analysis services to their customers. The company offers two certification paths: Agilent’s CGH microarray platform and its upstream target enrichment next-generation sequencing platform. Hands-on training is also provided by field application scientists to ensure customers receive consistent data quality, reproducibility and reliability.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts